Studies of absorption, excretion, antibacterial and clinical effect of cephalexin.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000362:Agar; D000368:Aged; D002177:Candidiasis / Q000150:complications; D002511:Cephalosporins / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011511:Proteus / Q000187:drug effects; D011512:Proteus Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013291:Streptococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy; D014848:Vulvovaginitis / Q000150:complications
D002511:Cephalosporins; D000362:Agar